A share price of Inozyme Pharma Inc [INZY] is currently trading at $6.11, up 7.01%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The INZY shares have gain 4.98% over the last week, with a monthly amount glided 31.40%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference. In a post published today on Yahoo Finance, – Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion -.
From an analyst’s perspective:
Inozyme Pharma Inc [NASDAQ: INZY] stock has seen the most recent analyst activity on March 23, 2023, when Jefferies upgraded its rating to a Buy and also boosted its price target to $6 from $4.50. Previously, Jefferies started tracking the stock with Hold rating on May 26, 2022, and set its price target to $5. On February 07, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $33 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $23 on November 29, 2021. Wedbush initiated its recommendation with a Outperform and recommended $35 as its price target on August 18, 2020. Piper Sandler started tracking with a Overweight rating for this stock on August 18, 2020, and assigned it a price target of $40. In a note dated August 18, 2020, Cowen initiated an Outperform rating.
Inozyme Pharma Inc experienced fluctuations in its stock price throughout the past year between $2.51 and $7.33. Currently, Wall Street analysts expect the stock to reach $40 within the next 12 months. Inozyme Pharma Inc [NASDAQ: INZY] shares were valued at $6.11 at the most recent close of the market. An investor can expect a potential return of 554.66% based on the average INZY price forecast.
Analyzing the INZY fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.79 points at the first support level, and at 5.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.27, and for the 2nd resistance point, it is at 6.44.
Inozyme Pharma Inc [INZY] reported earnings per share of -$0.29 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.32/share, meaning a difference of $0.03 and a surprise factor of 9.40%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.35 per share as compared to estimates of -$0.43 per share, a difference of $0.08 representing a surprise of 18.60%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Inozyme Pharma Inc [NASDAQ:INZY] is 16.36. As well, the Quick Ratio is 16.36, while the Cash Ratio is 0.05.
Transactions by insiders
Recent insider trading involved Hopfner Robert Lorne, Director, that happened on Aug 01 when 0.83 million shares were purchased. Director, Pivotal bioVenture Partners Fu completed a deal on Aug 01 to buy 0.83 million shares. Meanwhile, Director Hopfner Robert Lorne bought 0.23 million shares on May 12.
